Skip to Content

Cancer Imaging Program

  1. Contact Us

Research & Funding

Past CIP InitiativesRSS

This page lists past opportunities from CIP.

Requests for Application (RFA) are usually announced with special application dates; there is no possibility for applying after that date. Program Announcements (PA, PAR) may be open for a set period of time, such as 3 years or less; applications submitted in response to Program Announcements may be due on the standard dates (February 1, June1, and October 1) or may have special dates for receipt of applications. Please pay attention to these dates. Contact a CIP staff member if you have questions.

  • PAR-05-114: Quick-Trials for Imaging and Image-Guided Interventions: Exploratory Grants

    • Release Date: May 20, 2005
    • Application Receipt Date: August 9, December 9, April 9, 2005 through 2008
    • Contacts:

      Lalitha Shankar, M.D., (shankarl@mail.nih.gov) at 301-495-9531
      Keyvan Farahani, Ph.D. (farahank@mail.nih.gov) at 301-451-2651

    The goal of this program is to fund applications focused on the following areas of research: 1) Phase I or II clinical trials of novel imaging-agents to assure their safety and efficacy, so that further evaluations of the clinical potentials of these agents can proceed; 2) Feasibility studies in image-guided intervention, to establish treatment parameters and early therapeutic efficacy for these methods; and/or 3) Clinical feasibility or "proof-of-principle" studies or clinical trials to demonstrate potential efficacy of promising discoveries in imaging or image-guided therapy methodologies or technologies. Investigators may apply for a maximum of 2 years of funding support using the exploratory or developmental (R21) grant mechanism for up to $250,000 direct costs per year. The anticipated number of awards is three to six per year.

    See full description in NIH Guide:PAR-05-114

  • PAR-04-155: Quick Trials for Novel Cancer Therapies: Exploratory Grants

    This PA is intended to provide investigators with rapid access to support for pilot, Phase I, and Phase II cancer clinical trials as well as patient monitoring and laboratory studies. The focus of this QUICK-TRIAL PA is on translational research in new agent or device development to ensure the timely exploitation of new cancer therapeutic. This PA is aimed at providing a new approach in the grant application process by offering a rapid turnaround from application submission to funding. Features of this initiative include a modular grant application and award process, inclusion of the clinical protocol within the grant application, and accelerated peer review with the goal of issuing new awards within six months of application receipt. In addition, QUICK-TRIAL applications do not require extensive preliminary data in the grant application and support exploratory translational and clinical research studies involving cancer prevention, chemotherapy and rapid development and application of novel clinical cancer therapies including image guided therapeutic procedures. Investigators may apply for a maximum of two years of funding support using the exploratory or developmental (R21) grant mechanism for up to $250,000 direct costs per year.

    • Application Receipt Dates: December 9, 2004; April 9, 2005; August 9, 2005; December 9, 2005; April 9, 2006; August 9, 2006; December 9, 2006; April 9, 2007; August 9, 2007; December 9, 2007

    See full description in NIH Guide:PAR-04-155

  • PA-04-095: Novel Technologies for In Vivo Imaging (R21/R33)

    This Program Announcement (PA) replaces PAR-03-124.

    The NCI invites applications for the development and delivery of novel image acquisition or enhancement technologies and methods for biomedical imaging and image-guided interventions and therapy, and which may incorporate limited pilot or clinical feasibility evaluations using either pre-clinical models or clinical studies. This initiative is primarily intended to facilitate the proof-of-feasibility, development, and delivery of novel imaging technologies for early detection, screening, diagnosis, image-guided interventions, and treatment of various diseases, and, secondarily, to facilitate limited evaluation studies to show proof-of-concept and functionality.

    See full description in NIH Guide: PA-04-095

    What is the R21 grant mechanism?
    What is the R33 grant mechanism?

  • PA-04-094: Novel Technologies for In Vivo Imaging (SBIR/STTR)

    This Program Announcement (PA) replaces PAR-03-125.

    The NCI Cancer Imaging Program and Radiation Research Program, and the NIEHS, NIDDK, and NINDS invite applications for the development and delivery of novel in vivo image acquisition or enhancement technologies and methods for biomedical imaging and image-guided interventions and therapy. Applications may incorporate limited pilot or clinical feasibility evaluations using either pre-clinical models or clinical studies. This initiative is primarily intended to facilitate the proof-of-feasibility, development, and delivery of novel imaging technologies for early detection, screening, diagnosis, image-guided interventions and treatments of various diseases, and, secondarily, to facilitate limited evaluation studies to show proof-of-concept and functionality.

    See full description in NIH Guide:PA-04-094

  • PAR-04-069: In Vivo Cellular and Molecular Imaging Centers (ICMICS)

    • Release Date: February 27, 2004
    • Application Receipt Date: July 22, 2004; July 21, 2005
    • Contacts:

      Anne E. Menkens, Ph.D. (am187k@nih.gov) at 301-435-9024

    The Cancer Imaging Program, Division of Cancer Diagnosis and Treatment of the National Cancer Institute (NCI), invites applications for new or competing P50 Research Center Grants for In Vivo Cellular and Molecular Imaging Centers (ICMICs). This initiative is designed to capitalize on the extraordinary opportunity for molecular imaging to have an impact on the diagnosis and treatment of cancer patients non-invasively and quantitatively. Molecular imaging technologies can provide valuable laboratory tools for the interrogation of biological pathways relevant to cancer, as well as to provide imaging agents and technologies that will be directly utilized in the clinic. The 5-year P50 ICMIC grants described in this PAR are designed to bring together interdisciplinary scientific teams to lead the nation in cutting-edge cancer molecular imaging research with clinical relevance, provide unique core facilities to support oncology imaging research, provide flexibility to respond to exciting pilot research opportunities, and provide interdisciplinary career development opportunities for investigators new to the field of molecular cancer imaging. The P50 mechanism will promote coordination, interrelationships and scientific synergy among the research components and resources, leading to a highly integrated imaging center.

    • Letter of Intent Receipt Date(s): June 22, 2004; June 21, 2005

    See full description in NIH Guide:PAR-04-069

  • PA-04-063: An SBIR/STTR Initiative for Image-Guided Cancer Interventions

    • Release Date: February 17, 2004
    • Application Receipt Date: April 1, August 1, and December 1
    • Contacts:

      Keyvan Farahani, Ph.D. (farahank@mail.nih.gov) at 301-451-2651

    The purpose of this Program Announcement (PA) is to support the development and clinical validation of systems for image-guided interventions (IGI) for cancer. Specifically, the goals of this program are to provide support for: the development and optimization of fully integrated cancer imaging, monitoring, and therapy systems; validation of integrated IGI systems through clinical evaluations; the development of multiple prototype integrated IGI systems as required for multi-site clinical evaluations; and partnerships among small business, large business, and academic clinical centers, as well as small business joint ventures, in order to reach the research goals.

    • SBIR set-aside

    See full description in NIH Guide:PA-04-063

    What is SBIR?
    What is STTR?

  • RFA: CA-05-007: Application of Emerging Technologies for Cancer Research (SBIR/STTR)

    • Release Date: January 07, 2004
    • Application Receipt Date: March 10, 2004; June 17, 2004; October 18, 2004
    • Contacts:

      Barbara Y. Croft, Ph.D. (bc129b@nih.gov) at 301-496-9531

    The NCI invites applications for research projects to evaluate the usefulness of emerging technologies that are ready for initial application to clinical or biological questions in cancer research. Projects should be designed to demonstrate that the technology is robust and yields reproducible measurements, as well as be designed to gather preliminary data to support the use of the technology in a future project(s) with a clinical or biological focus.

    • Letter of Intent Receipt Date(s): February 10, 2004; May 17, 2004; September 17, 2004

    See full description in NIH Guide: RFA: CA-05-007

  • NCI RFA: CA-05-006: Innovative Technologies for Molecular Analysis of Cancer (SBIR/STTR)

    • Release Date: January 07, 2004
    • Application Receipt Date: March 10, 2004; June 17, 2004; October 18, 2004
    • Contacts:

      Barbara Y. Croft, Ph.D. (bc129b@nih.gov) at 301-496-9531

    The NCI invites applications for research projects proposing the development of highly innovative cancer relevant technologies, encompassing methods and tools that enable research, including, but not limited to, instrumentation, techniques, and devices. Technology is distinct from resources such as databases, reagents, and tissue repositories.

    • Letter of Intent Receipt Date(s): February 10, 2004; May 17, 2004; September 17, 2004

    See full description in NIH Guide:RFA: CA-05-006

  • PA-04-045: In Vivo Cancer Imaging Exploratory/Developmental Grants (R21)

    • Release Date: December 24, 2003
    • Application Receipt Date: February 1, June 1, and October 1
    • Contacts:

      Anne E. Menkens, Ph.D. (am187k@nih.gov) at 301-435-9024

    The Cancer Imaging Program (CIP) of the Division of Cancer Treatment and Diagnosis (DCTD) solicits exploratory/developmental (R21) applications that articulate exploratory/developmental research focused on in vivo cancer imaging. The R21 mechanism will provide investigators at all career levels with a defined level of funding adequate for the initial development and/or feasibility testing of high impact concepts. Topics considered responsive to this Program Announcement will cover the entire spectrum of in vivo cancer imaging research, from basic discovery of new cancer imaging agents and technologies, through pre-clinical testing and validation, to the early feasibility testing of those novel agents and technologies in small clinical trials. The applicant may request a project period of up to two years with a combined budget for direct costs of up $275,000 for the two year period.

    • No set-aside

    See full description in NIH Guide:PA-04-045

  • PA-04-046: Clinical Cancer Therapy and Prevention Research

    • Release Date: December 24, 2003
    • Application Receipt Date: February 1, June 1, and October 1
    • Contacts:

      Keyvan Farahani, Ph.D. (farahank@mail.nih.gov) at 301-451-2651

    The NCI is seeking R01 applications to conduct translational, clinical, therapeutic, and preventive studies/trials of neoplastic diseases in humans and encourages clinical researchers to collaborate with basic scientists to translate insights in cancer biology and the development of new anti-cancer agents into innovative cancer intervention studies/trials. The overall aims of this renewed PA are two-fold: (1) to stimulate development of innovative therapeutic/preventive clinical trials with or without laboratory correlative studies (2) to support innovative correlative laboratory studies linked to therapeutic/preventive clinical trials. Investigators may address either aim in their applications.

    • No set-aside

    See full description in NIH Guide:PA-04-046

U.S. Department of Health and Human Services  |  National Institutes of Health  |  National Cancer Institute  |  USA.gov

NIH…Turning Discovery Into Health®